person · Reporting owner

Johnson David Michael

Disclosed activity across 2 companies

Tapewire entity: 37036
SEC CIK: 0001808098

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aura Biosciences, Inc.AURA · Entity 5142	Director	June 11, 2026	June 15, 2026
Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772	Director	June 16, 2026	June 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aura Biosciences, Inc.

Report date June 11, 2026 · Filed June 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	194,167	Reported balance After 2026-06-11 transaction · row 1 1 source row Row 1 · 2026-06-11 · Grant · Acquired 15,000 · Balance 194,167 F1: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.21 · Expires 2036-06-11	Direct	30,000	Reported balance After 2026-06-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-06-11 · Grant · Acquired 30,000 · Balance 30,000 F5: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.
Common StockSEC Table I · non-derivative	IndirectBy NEJ09 IRREVOCABLE TRUST	75,000	Reported balance Holding disclosure · report date 2026-06-11 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 75,000 F2: The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee.
Common StockSEC Table I · non-derivative	IndirectBy NEJ12 IRREVOCABLE TRUST	75,000	Reported balance Holding disclosure · report date 2026-06-11 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 75,000 F3: The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee.
Common StockSEC Table I · non-derivative	IndirectBy Velocity Capital Management	139,672	Reported balance Holding disclosure · report date 2026-06-11 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 139,672 F4: Velosity Capital Management LLC is an entity that the Reporting Person is the sole member of.

Filing footnotes · ownership attribution and instrument terms

F1: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.

F2: The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee.

F3: The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee.

F4: Velosity Capital Management LLC is an entity that the Reporting Person is the sole member of.

F5: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.

Zentalis Pharmaceuticals, Inc.

Report date June 16, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	307,521	Reported balance After 2026-06-16 transaction · row 1 1 source row Row 1 · 2026-06-16 · Grant · Acquired 57,100 · Balance 307,521 F1: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 02, 2020 Filed Dec 3, 2020 22:57 UTC	Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772	SaleCommon Stock	4,603	$51.61	$237,560.83	Disclosure SEC source: 0001725160-20-000052 · wf-form4_160703623563271.xml · nonDerivative · entry 4 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,577 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.32 to $52.26. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 02, 2020 Filed Dec 3, 2020 22:57 UTC	Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772	SaleCommon Stock	3,868	$50.82	$196,571.76	Disclosure SEC source: 0001725160-20-000052 · wf-form4_160703623563271.xml · nonDerivative · entry 3 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,180 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.32 to $51.31. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 02, 2020 Filed Dec 3, 2020 22:57 UTC	Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772	SaleCommon Stock	1,600	$49.80	$79,680.00	Disclosure SEC source: 0001725160-20-000052 · wf-form4_160703623563271.xml · nonDerivative · entry 2 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,048 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.30 to $50.22. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
April 07, 2020 Filed Apr 9, 2020 20:31 UTC	Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772	GrantCommon Stock	51,587	$0.00	$0.00	Disclosure SEC source: 0000899243-20-010605 · doc4.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,648 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest over a twenty-four month period following the grant date. Read SEC document
April 07, 2020 Filed Dec 3, 2020 22:57 UTC	Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772	PurchaseCommon Stock	4,000	$18.00	$72,000.00	Disclosure SEC source: 0001725160-20-000052 · wf-form4_160703623563271.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,648 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.